Spravato® is a prescription medicine containing esketamine. It has specific FDA-approved uses and important safety requirements. Only a qualified clinician can determine whether it may be appropriate for an individual.
Why a careful evaluation is important
Treatment decisions require a thorough review of symptoms, prior treatment, medical history, current medications, and safety considerations. An evaluation can help a clinician discuss potential benefits, limitations, alternatives, and whether referral or another approach may be more suitable.
Eligibility and treatment plans are individualized. This overview is not a screening tool or a recommendation for treatment.
Supervision and monitoring
Because Spravato® can cause sedation, dissociation, and other serious effects, it must be administered in a certified healthcare setting under a Risk Evaluation and Mitigation Strategy (REMS) program. People receiving treatment are monitored after administration and should follow their care team's transportation and safety instructions.
Ask a clinician to explain the current prescribing information, monitoring process, and practical expectations before making a decision.
Bring these questions to a clinician
A conversation may include:
- What is the intended role of this treatment in my care plan?
- What safety information and monitoring requirements apply?
- What alternatives should we discuss based on my history and goals?